Recent developments in cyclin-dependent kinase biochemical and structural studies

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1804, Issue 3, 2010, Pages 511-519

  Echalier, Aude ^a   Endicott, Jane A ^a   Noble, Martin E M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

CDK; Cell cycle regulation; Cyclin; X ray crystallography

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 9;

ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME STRUCTURE; PRIORITY JOURNAL; REVIEW;

ANIMALS; CYCLIN-DEPENDENT KINASES; CYCLINS; HUMANS; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; SUBSTRATE SPECIFICITY;

EID: 75349112388     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2009.10.002     Document Type: Review

References (58)

1. Morgan D.O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 13 (1997) 261-291
2. Malumbres M., and Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci. 30 (2005) 630-641
3. Sherr C.J., and Roberts J.M. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 18 (2004) 2699-2711
4. Mailand N., and Diffley J.F. CDKs promote DNA replication origin licensing in human cells by protecting Cdc6 from APC/C-dependent proteolysis. Cell 122 (2005) 915-926
5. Fisher R.P. Secrets of a double agent: CDK7 in cell-cycle control and transcription. J. Cell. Sci. 118 (2005) 5171-5180
6. Wang S., and Fischer P.M. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol. Sci. 29 (2008) 302-313
7. Johnson L.N. Protein kinase inhibitors: contributions from structure to clinical compounds. Q. Rev. Biophys. 42 (2009) 1-40
8. Hayward N.K. Genetics of melanoma predisposition. Oncogene 22 (2003) 3053-3062
9. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24 (2006) 1770-1783
10. Pavletich N.P. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J. Mol. Biol. 287 (1999) 821-828
11. Huse M., and Kuriyan J. The conformational plasticity of protein kinases. Cell 109 (2002) 275-282
12. Barrett C.P., and Noble M.E. Molecular motions of human cyclin-dependent kinase 2. J. Biol. Chem. 280 (2005) 13993-14005
13. Baumli S., Lolli G., Lowe E.D., Troiani S., Rusconi L., Bullock A.N., Debreczeni J.E., Knapp S., and Johnson L.N. The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO J. 27 (2008) 1907-1918
14. Day P.J., Cleasby A., Tickle I.J., O'Reilly M., Coyle J.E., Holding F.P., McMenamin R.L., Yon J., Chopra R., Lengauer C., and Jhoti H. Crystal structure of human CDK4 in complex with a D-type cyclin. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 4166-4170
15. Takaki T., Echalier A., Brown N.R., Hunt T., Endicott J.A., and Noble M.E. The structure of CDK4/cyclin D3 has implications for models of CDK activation. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 4171-4176
16. Jeffrey P.D., Tong L., and Pavletich N.P. Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors. Genes Dev. 14 (2000) 3115-3125
17. Honda R., Lowe E.D., Dubinina E., Skamnaki V., Cook A., Brown N.R., and Johnson L.N. The structure of cyclin E1/CDK2: implications for CDK2 activation and CDK2-independent roles. EMBO J. 24 (2005) 452-463
18. Huang K., Ferrin-O'Connell I., Zhang W., Leonard G.A., O'Shea E.K., and Quiocho F.A. Structure of the Pho85-Pho80 CDK-cyclin complex of the phosphate-responsive signal transduction pathway. Mol. Cell 28 (2007) 614-623
19. Brown N.R., Noble M.E., Endicott J.A., and Johnson L.N. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. Cell Biol. 1 (1999) 438-443
20. Brown N.R., Lowe E.D., Petri E., Skamnaki V., Antrobus R., and Johnson L.N. Cyclin B and cyclin A confer different substrate recognition properties on CDK2. Cell Cycle 6 (2007) 1350-1359
21. Song H., Hanlon N., Brown N.R., Noble M.E., Johnson L.N., and Barford D. Phosphoprotein-protein interactions revealed by the crystal structure of kinase-associated phosphatase in complex with phosphoCDK2. Mol. Cell 7 (2001) 615-626
22. Tarricone C., Dhavan R., Peng J., Areces L.B., Tsai L.H., and Musacchio A. Structure and regulation of the CDK5-p25(nck5a) complex. Mol. Cell 8 (2001) 657-669
23. Owen D.J., Noble M.E., Garman E.F., Papageorgiou A.C., and Johnson L.N. Two structures of the catalytic domain of phosphorylase kinase: an active protein kinase complexed with substrate analogue and product. Structure 3 (1995) 467-482
24. Merckx A., Echalier A., Langford K., Sicard A., Langsley G., Joore J., Doerig C., Noble M., and Endicott J. Structures of P. falciparum protein kinase 7 identify an activation motif and leads for inhibitor design. Structure 16 (2008) 228-238
25. Takizawa C.G., and Morgan D.O. Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. Curr. Opin. Cell Biol. 12 (2000) 658-665
26. Zhou B.B., and Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature 408 (2000) 433-439
27. Donzelli M., and Draetta G.F. Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep. 4 (2003) 671-677
28. Bartek J., Lukas C., and Lukas J. Checking on DNA damage in S phase. Nat. Rev. Mol. Cell Biol. 5 (2004) 792-804
29. Welburn J.P., Tucker J.A., Johnson T., Lindert L., Morgan M., Willis A., Noble M.E., and Endicott J.A. How tyrosine 15 phosphorylation inhibits the activity of cyclin-dependent kinase 2-cyclin A. J. Biol. Chem. 282 (2007) 3173-3181
30. Mapelli M., Massimiliano L., Crovace C., Seeliger M.A., Tsai L.H., Meijer L., and Musacchio A. Mechanism of CDK5/p25 binding by CDK inhibitors. J. Med. Chem. 48 (2005) 671-679
31. Bartova I., Koca J., and Otyepka M. Regulatory phosphorylation of cyclin-dependent kinase 2: insights from molecular dynamics simulations. J. Mol. Model 14 (2008) 761-768
32. Smith D.S., and Tsai L.H. Cdk5 behind the wheel: a role in trafficking and transport?. Trends Cell Biol. 12 (2002) 28-36
33. Otyepka M., Bartova I., Kriz Z., and Koca J. Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics. J. Biol. Chem. 281 (2006) 7271-7281
34. Songyang Z., Blechner S., Hoagland N., Hoekstra M.F., Piwnica-Worms H., and Cantley L.C. Use of an oriented peptide library to determine the optimal substrates of protein kinases. Curr. Biol. 4 (1994) 973-982
35. Lolli G., and Johnson L.N. CAK-Cyclin-dependent activating kinase: a key kinase in cell cycle control and a target for drugs?. Cell Cycle 4 (2005) 572-577
36. Larochelle S., Chen J., Knights R., Pandur J., Morcillo P., Erdjument-Bromage H., Tempst P., Suter B., and Fisher R.P. T-loop phosphorylation stabilizes the CDK7-cyclin H-MAT1 complex in vivo and regulates its CTD kinase activity. EMBO J. 20 (2001) 3749-3759
37. Larochelle S., Batliner J., Gamble M.J., Barboza N.M., Kraybill B.C., Blethrow J.D., Shokat K.M., and Fisher R.P. Dichotomous but stringent substrate selection by the dual-function Cdk7 complex revealed by chemical genetics. Nat. Struct. Mol. Biol. 13 (2006) 55-62
38. Garrett S., Barton W.A., Knights R., Jin P., Morgan D.O., and Fisher R.P. Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop. Mol. Cell. Biol. 21 (2001) 88-99
39. Lowe E.D., Tews I., Cheng K.Y., Brown N.R., Gul S., Noble M.E., Gamblin S.J., and Johnson L.N. Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A. Biochemistry 41 (2002) 15625-15634
40. Wohlschlegel J.A., Dwyer B.T., Takeda D.Y., and Dutta A. Mutational analysis of the Cy motif from p21 reveals sequence degeneracy and specificity for different cyclin-dependent kinases. Mol. Cell. Biol. 21 (2001) 4868-4874
41. Cheng K.Y., Noble M.E., Skamnaki V., Brown N.R., Lowe E.D., Kontogiannis L., Shen K., Cole P.A., Siligardi G., and Johnson L.N. The role of the phospho-CDK2/cyclin A recruitment site in substrate recognition. J. Biol. Chem. 281 (2006) 23167-23179
42. Takeda D.Y., Wohlschlegel J.A., and Dutta A. A bipartite substrate recognition motif for cyclin-dependent kinases. J. Biol. Chem. 276 (2001) 1993-1997
43. Russo A.A., Jeffrey P.D., Patten A.K., Massague J., and Pavletich N.P. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 382 (1996) 325-331
44. James M.K., Ray A., Leznova D., and Blain S.W. Differential modification of p27Kip1 controls its cyclin D-cdk4 inhibitory activity. Mol. Cell. Biol. 28 (2008) 498-510
45. LaBaer J., Garrett M.D., Stevenson L.F., Slingerland J.M., Sandhu C., Chou H.S., Fattaey A., and Harlow E. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11 (1997) 847-862
46. Cheng M., Olivier P., Diehl J.A., Fero M., Roussel M.F., Roberts J.M., and Sherr C.J. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 18 (1999) 1571-1583
47. Larrea M.D., Liang J., Da Silva T., Hong F., Shao S.H., Han K., Dumont D., and Slingerland J.M. Phosphorylation of p27Kip1 regulates assembly and activation of cyclin D1-Cdk4. Mol. Cell. Biol. 28 (2008) 6462-6472
48. Ray A., James M.K., Larochelle S., Fisher R.P., and Blain S.W. p27Kip1 inhibits cyclin D-cyclin-dependent kinase 4 by two independent modes. Mol. Cell. Biol. 29 (2009) 986-999
49. Malumbres M., and Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9 (2009) 153-166
50. Satyanarayana A., and Kaldis P. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 28 (2009) 2925-2939
51. Hochegger H., Takeda S., and Hunt T. Cyclin-dependent kinases and cell-cycle transitions: does one fit all?. Nat. Rev. Mol. Cell Biol. (2008) 9
52. Brandeis M., Rosewell I., Carrington M., Crompton T., Jacobs M.A., Kirk J., Gannon J., and Hunt T. Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die in utero. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 4344-4349
53. Geng Y., Yu Q., Sicinska E., Das M., Schneider J.E., Bhattacharya S., Rideout W.M., Bronson R.T., Gardner H., and Sicinski P. Cyclin E ablation in the mouse. Cell 114 (2003) 431-443
54. Kozar K., Ciemerych M.A., Rebel V.I., Shigematsu H., Zagozdzon A., Sicinska E., Geng Y., Yu Q., Bhattacharya S., Bronson R.T., Akashi K., and Sicinski P. Mouse development and cell proliferation in the absence of D-cyclins. Cell 118 (2004) 477-491
55. Murphy M., Stinnakre M.G., Senamaud-Beaufort C., Winston N.J., Sweeney C., Kubelka M., Carrington M., Brechot C., and Sobczak-Thepot J. Delayed early embryonic lethality following disruption of the murine cyclin A2 gene. Nat. Genet. 15 (1997) 83-86
56. Santamaria D., Barriere C., Cerqueira A., Hunt S., Tardy C., Newton K., Caceres J.F., Dubus P., Malumbres M., and Barbacid M. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 448 (2007) 811-815
57. Krissinel E., and Henrick K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372 (2007) 774-797
58. Clamp M., Cuff J., Searle S.M., and Barton G.J. The Jalview Java alignment. Bioinformatics vol. 20 (2004) 426-427